All In Biotech

Drug Trial Radar · NCT04234594

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

A Randomized, Double-blind and Single-dose Study to Compare the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Male Subjects.

Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

94

Planned (sponsor's estimate)

Start

Oct 28, 2019

Primary completion

Sep 30, 2020

Study completion Sep 30, 2020

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety of QL1203 and Vectibix® in healthy males.

Conditions

  • Healthy Males

Interventions

  • QL1203Drug

    6 mg/kg intravenous (IV) infusion only once,on the first day.

  • Vectibix®Drug

    6 mg/kg intravenous (IV) infusion only once,on the first day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve (AUC0-t )Time frame: 36 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Guizhou Cancer Hospital

    Guiyang, Guizhou, China · Recruiting

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.